Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region”In the company’s words, NCT05520970 on ClinicalTrials.gov
- Main trialPhase 2
- “The immunogenicity and safety profiles of AdCLD-CoV19-1 (5.0×10\^10 VP/dose) will be assessed for 1-dose or 2-dose regimen in SARS-CoV-2 seronegative healthy adults.”In the company’s words, NCT05520970 on ClinicalTrials.gov
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 8 Nov 2022 | Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 | |
| Phase 1Completed | 2 Dec 2022 | Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026